Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag for secondary prevention of chemotherapy-induced thrombocytopenia in rare tumors (Phase 2)
ChiCTR2600128199Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eltrombopag in Non-hematologic malignancy and chemotherapy-induced thrombocytopenia (CIT), sponsored by Shandong Cancer Hospital. Primary endpoint: Incidence of PLT < 50 × 10^9/L during this treatment cycle. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
eltrombopag
03
Conditions
Non-hematologic malignancychemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on ChiCTR2600128199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128199.